Form 4: ELUTIA INC. Director David Colpman Granted 60,339 Stock Options Under Compensation Program

ELUTIA INC. Director David Colpman was granted 60,339 stock options with an exercise price of $1.65 per share, as part of the company's Non-Employee Director Compensation Program.

Summary

• David Colpman, a Director of ELUTIA INC. (ELUT), was granted 60,339 stock options on May 29, 2025.
• The options have an exercise price of $1.65 per share and an expiration date of May 29, 2035.
• These options were automatically granted under the Issuer's Non-Employee Director Compensation Program.
• The options will vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the grant date, or (ii) the first anniversary of the grant date.
• Vesting is contingent upon Mr. Colpman's continued service on the Issuer's board of directors through the applicable vesting date.
• Following this transaction, Mr. Colpman beneficially owns 60,339 derivative securities directly.

Sentiment

Score: 5

Explanation: The document reports a routine compensation event (stock option grant) to a director, which is a neutral event in terms of immediate company performance or outlook. It reflects standard corporate governance and compensation practices.

Positives

• The grant of stock options to Director David Colpman aligns his interests with those of shareholders, as the options gain value if the stock price increases above the exercise price.

Negatives

• No specific negative points are indicated by this routine compensation filing.

Risks

• The value of the granted stock options is subject to the future performance of ELUTIA INC.'s stock price; if the stock price does not exceed the exercise price of $1.65, the options may expire worthless.

Future Outlook

The stock options granted to Director David Colpman are subject to a vesting schedule, becoming exercisable on the earlier of the day preceding the Issuer's first annual meeting following the grant date or the first anniversary of the grant date, provided he continues his service on the board.

Industry Context

This filing represents a standard compensation practice for non-employee directors in publicly traded companies, aiming to incentivize long-term commitment and align director interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of a non-employee director compensation program is a common practice across various industries, including biotechnology and pharmaceuticals, where companies like Moderna (MRNA) or BioNTech (BNTX) also utilize equity-based compensation to attract and retain talent.
• The specific number of options (60,339) and the exercise price ($1.65) would need to be compared against ELUTIA's market capitalization and peer group compensation practices to assess if it is within typical industry ranges for a director of a company of similar size and stage.

Corporate Governance

Related Party Transactions

• The grant of 60,339 stock options to David Colpman, a Director of ELUTIA INC., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options to a director is a form of non-cash compensation that aligns the director's interests with shareholder value creation, as the options' value is tied to stock price appreciation.
• Employees: This specific filing does not directly impact general employees, as it pertains to director compensation.

Next Steps

• The granted stock options will vest and become exercisable on the earlier of the day preceding the Issuer's first annual meeting following the grant date or the first anniversary of the grant date.

Key Dates

Keywords

ELUTIA INC., ELUT, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership